### CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being filed with Dianne Maggard of the United States Patent and Trademark Office by facsimile transmission on October 20, 2005 to facsimile telephone number (571) 273-0300.

40,162

(Reg. No.)

ij

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appellant(s):

Walke et al.

Group Art Unit: 1652

Application No.:

09/783,320

Appeal No.: 2005-2440

Filed:

February 15, 2001

Examiner: D.M. Ramirez

Title: Novel Human Kinases and

Polynucleotides Encoding the Same

Atty. Docket No. LEX-0137-USA

## RESPONSE TO ORDER UNDER 37 C.F.R. § 41.50(d) DATED SEPTEMBER 22, 2005; AND WITHDRAWAL OF APPEAL

Mail Stop Appeal Brief - Patents Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

ij

Appellants acknowledge the receipt of the Order under 37 C.F.R. § 41.50(d)("the Order") in the above-referenced case, mailed on September 22, 2005, which has been carefully reviewed and studied. Appellants herein respond as ordered.

## RESPONSE

As stated in the Order, "we require Appellants to explain why we should again address the same line of argument in this case; since the same arguments were considered and thoroughly addressed in Appeal No. 2004-1732, why would the previous panel's treatment of those arguments not be dispositive here?" (Order at page 4 lines 16-19),

Appellants note that while Appeal No. 2004-1732 and the present Appeal do share some issues, several of the arguments in the present Appeal are unique. Appellants further note (with some confusion as to why the Order was a necessity in the first place), that while the Board's position in the Order is that essentially the same arguments have been previously considered, clearly they appear to recognize that the present Appeal Brief contained additional unique arguments. This is evidenced by what would appear to be footnote 3, in which the Board attempts to discount there differentiating facts and arguments (the Order at the bottom of page 4). Although the Board has briefly addressed these new arguments in "footnote 3", Appellants respectfully question whether a footnote in an Order Under 37 C.F.R. § 41.50(d) is the proper forum for the disposition of new arguments not previously considered by the Board. As set forth by the U.S. Court of Appeals for the Federal Circuit ("The Federal Circuit") in Gechter v. Davidson (43 USPQ2d 1030, (Fcd. Cir., 1997)), "the Board is required to set forth in its opinions specific findings of fact and conclusions of law adequate to form a basis for our review" (emphasis added). To the best of Appellants' knowledge, only a final Decision on Appeal from the Board is appealable to the Federal Circuit, not an Order Under 37 C.F.R. § 41.50(d), presently leaving Appellants no forum to argue the Board's disposition of the new arguments set forth in the Appeal Brief in the present case, as detailed in "footnote 3"...

Thus, inter alia, the matters that differentiate the present Appeal from that of Appeal No. 2004-1732 are that, in addition to referring to unique sequences, the instant Appeal Brief describes evidence that those of skill in the art would readily recognize the instant molecules as encoding the human kinase known as NEK-1 and that kinase proteins were a class of proteins with a very wellestablished, substantial and specific utility with a well defined and well-established function (phosphoylation) at the time this application was filed.

## WITHDRAWAL OF APPEAL

While Appellants do not agree with the rejections set forth by the Examiner in the present case, and do not agree with the Board that "The Appeal Brief in this appeal includes essentially the same arguments that were made and rejected by the previous merits panel in Appeal No. 2004-1732" (the Order at page 3), Appellants hereby withdraw the present appeal (Appeal No. 2005-2440) without prejudice and without disclaimer in order to pursue claims in a continuing application.

A one month non-extendable time limit for response is set forth in the Order. The response is therefore timely filed, and Appellants believe no fees are due in connection with this response. However, the Commissioner is authorized to charge any required fees or credit any overpayment to Deposit Account No. 50-0892.

Respectfully submitted,

October 20, 2005

Date

Peter G. Seferian

Reg. No. 40,162

Agent for Appellants

LEXICON GENETICS INCORPORATED (281) 863-3110

**Customer # 24231** 

8800 Technology Forest Place The Woodlands, TX 77381 Phone: 281-863-3110 Fax: 281-863-3335

# **Lexicon Genetics Incorporated**



To: Dianne Maggard From: Peter G. Seferian
Board of Patent Appeals and Interferences

Fax: 571-273-0300 Date: October 20, 2005

Phone: Pages: 4 (including coversheet)

Appeal No. 2005-2440
Re: Application Serial Number: 09/783,320 CC: File
Atty. Dkt. No. LEX-0137-USA

### •Comments:

Please find attached a Response to the Order Under 37 C.F.R. § 41.50(d) in reference to the above-referenced appeal. Please contact me at the number shown above if there are any questions.